- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cognition Therapeutics GAAP EPS of -$0.04 beats by $0.03 | 1 | Seeking Alpha | ||
| Do | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| Do | COGNITION THERAPEUTICS INC - 8-K, Current Report | - | SEC Filings | ||
| COGNITION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.11. | Cognition Therapeutics, Inc.: Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 | 1 | GlobeNewswire (USA) | ||
| 22.10. | Cognition Therapeutics erzielt Einigung mit FDA über Phase-3-Studiendesign bei Lewy-Körperchen-Demenz | 1 | Investing.com Deutsch | ||
| 22.10. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 22.10. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies | 1 | GlobeNewswire (USA) | ||
| 15.10. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent grant | 2 | Investing.com | ||
| 13.10. | Cognition Therapeutics receives patent for zervimesine form | 1 | Investing.com | ||
| 13.10. | Cognition Therapeutics, Inc.: Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045 | 4 | GlobeNewswire (USA) | ||
| 05.10. | H.C. Wainwright reiterates Cognition Therapeutics stock rating ahead of FDA meeting | 3 | Investing.com | ||
| 29.09. | Cognition Therapeutics: FDA-Treffen für Zulassungsstudie zu Demenz-Medikament angesetzt | 1 | Investing.com Deutsch | ||
| 29.09. | Cognition Therapeutics, Inc.: Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB | 1 | GlobeNewswire (USA) | ||
| 07.08. | COGNITION THERAPEUTICS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 06.08. | Cognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update | 259 | GlobeNewswire (Europe) | PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the "Company"... ► Artikel lesen | |
| 06.08. | COGNITION THERAPEUTICS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 13.07. | Cognition Therapeutics, Inc.: Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit | 1 | GlobeNewswire (USA) | ||
| 01.07. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on FDA alignment | 3 | Investing.com | ||
| 24.06. | Cognition Therapeutics, Inc.: Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes | 552 | GlobeNewswire (Europe) | - Zervimesine Would be the First Long-term, Durable Treatment Option with an Impact on Underlying Disease -- Company Developing NPI as a Measure of DLB Psychosis - PURCHASE, N.Y., June 24, 2026 (GLOBE... ► Artikel lesen | |
| 22.06. | H.C. Wainwright reiterates Cognition Therapeutics stock rating on patent news | 1 | Investing.com |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,55 | +0,58 % | Buy or Goodbye?: Teamviewer, Novo Nordisk, Biontech, Continental - Die Analystenstimmen des Tages | © Foto: Julian Stratenschulte/dpaTeamviewer, Novo Nordisk, Biontech, Continental: Die wichtigsten Analysten-Updates im Überblick Enthaltene Werte: DE0005439004,DE000A2YN900,US09075V1026,DK0062498333Den... ► Artikel lesen | |
| AMGEN | 414,00 | -0,64 % | ROUNDUP/Gefragte Kassenschlager: Amgen wird erneut etwas optimistischer | THOUSAND OAKS (dpa-AFX) - Das US-Biotechnologieunternehmen Amgen hat nach einem starken dritten Quartal mit hohen Wachstumsraten bei wichtigen Kassenschlagern abermals seine Umsatzprognose erhöht.... ► Artikel lesen | |
| NOVAVAX | 9,050 | -0,88 % | Novavax, Inc.: Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights | Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP Adjusted Total Revenue by $145 million to $400 million at mid-point and improves GAAP Combined R&D and... ► Artikel lesen | |
| BIOGEN | 222,55 | -1,87 % | Biogen Inc.: ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure | Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP... ► Artikel lesen | |
| BIOFRONTERA | 3,000 | +0,33 % | PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien | DJ PTA-News: Biofrontera AG: Biofrontera unterzeichnet Vertriebsvereinbarung mit Propaira Pty Ltd für Ameluz in Australien
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: Biofrontera... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,161 | -10,35 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights | VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) granted accelerated approval by U.S. Food and Drug Administration (FDA) to reduce the frequency of surgery in adults with Recurrent... ► Artikel lesen | |
| CLINUVEL | 4,524 | -1,09 % | CLINUVEL PHARMACEUTICALS LIMITED: Results of Meeting | ||
| VIKING THERAPEUTICS | 25,500 | -0,78 % | Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors. | ||
| INFLARX | 1,205 | +10,65 % | InflaRx: 2027 - warum die nächsten Studien jetzt zählen | ||
| INTELLIA THERAPEUTICS | 10,200 | +1,80 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TEMPUS AI | 74,02 | +2,62 % | Ihre wichtigsten Termine: Frische Q-Zahlen von Apple, Palantir, BioMarin, Marriott International, Fox Corp | © Foto: Andrej Sokolow - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: US0378331005... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,191 | -9,29 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Interest Payment | Montreal, Quebec--(Newsfile Corp. - October 23, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | +4,00 % | Editas auf der Guggenheim Healthcare Innovation Conference: Strategischer Fokus auf In-vivo-CRISPR | ||
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| NUREXONE BIOLOGIC | 0,317 | +3,93 % | 200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollen |
Das Unternehmen COGNITION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,676 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COGNITION THERAPEUTICS INC finden Sie auf Wallstreet Online.